



## LETTER ARTICLE


**BENTHAM  
SCIENCE**

## Prevention of COVID-19 Infection in the Medical Population: Possible Help from Anosmia?



Giuseppe Chiarella<sup>1,\*,#</sup>, Raffaella Pizzolato<sup>2,#</sup>, Donatella Malanga<sup>3,#</sup>, Davide Pisani<sup>1,#</sup>, Ludovico Abenavoli<sup>4,#</sup> and Pasquale Viola<sup>1,#</sup>

<sup>1</sup>Unit of Audiology, Department of Experimental and Clinical Medicine, Regional Centre for Cochlear Implants and ENT Diseases, University "Magna Graecia", Catanzaro, Italy; <sup>2</sup>Department of Neurology, University of Massachusetts, Medical School, Worcester, MA, USA; <sup>3</sup>Laboratory of Molecular Oncology, Department of Experimental and Clinical Medicine, University "Magna Graecia", Catanzaro, Italy; <sup>4</sup>Department of Health Sciences, University "Magna Graecia", Catanzaro, Italy

In December 2019, in Wuhan city, the capital of Hubei province in China, was reported the appearance of patients with pneumonia of unknown cause [1]. The Chinese scientists described a novel coronavirus (CoV) in bronchoalveolar-lavage samples of patients affected by severe pneumonia. Next-generation sequencing analysis indicated that the unknown genome showed more than 85% identity with those from a bat SARS-like CoV (bat-SL-CoVZC45, MG772933.1) [2]. In January, the Chinese authorities shared the full sequence of the novel coronavirus genome (GenBank: MN988668), making data available worldwide. This novel coronavirus was later designated as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease was named by the World Health Organization, as Coronavirus disease 2019 (COVID-19) in February 2020 [3]. The other two well-known beta coronaviruses able to induce severe disease in humans are the Severe Acute Respiratory Syndrome Coronavirus, SARS-CoV, and the Middle East Respiratory Syndrome Coronavirus, MERS-CoV [4]. SARS-CoV-2 made use of the spike glycoprotein S, and the envelope-anchored surface, to mediate entry into host cells. The receptor-binding domain of SARS-CoV spikes protein S that recognizes the angiotensin-converting enzyme 2 (ACE2) as host receptor [5-7], likely SARS-CoV [8]. The transmission from human-to-human is believed to occur through respiratory aerosol, droplets from coughing, and sneezing. The patient clinical features mostly resembled those observed for SARS-CoV and MERS-CoV infections. Most patients presented with fever, dry cough, dyspnoea, and bilateral ground-glass opacities on chest CT scans, SARS-CoV-2 patients rarely developed intestinal signs and symptoms (for example, diarrhea) [9, 10].

As infection is spreading globally, clinical characteristics of COVID-19 remain unclear. It is the uncertainty of the

clinical characteristics of these patients that the asymptomatic cases increase the risks of disease dissemination with an even higher risk for physicians, given the shortage of protective equipment [11].

There are ever-growing information and reports that come from Colleagues, nationally and internationally. They arrive more quickly than the indications that literature can provide. In these reports, the frequent finding of anosmia or hyposmia emerges even in the absence of other typical symptoms of COVID-19 and or nasal findings.

Otolaryngologists and Audiologists based in the various Italian Regions were quickly consulted, that confirmed these findings. In Bergamo, a city in the north part of Italy, the epicentre of COVID-19 epidemic, anosmia resulted as a frequent initial symptom. This epidemiological trend was confirmed by our Colleagues in few Italian regions, in particular in Marche (cities of Ancona, Macerata, Ascoli Piceno), Tuscany (cities of Empoli, Prato and Florence), Lombardia (city of Rozzano), and Lazio (city of Fondi). All of them are observing an increased number of cases of anosmia in otherwise healthy patients, compared to the usual epidemiological trend. International confirmations arrived from the United States, Germany, France, Korea, and China. In South Korea, where testing is widely performed, about 30% of patients experienced anosmia as the main symptom, in a rather mild clinical picture.

The pathophysiology of other coronaviruses (CoVs) might help clarify this finding. The neurotropic and neuroinvasive capabilities of different CoVs are described in several of their hosts, including humans [12, 13]. A possible route for neuroinvasion is the retrograde transport along axons of olfactory neurons [14]. The olfactory nerve is in communication with the nasal epithelium and with the olfactory bulb, which has direct contact with the CNS and is an immunoeffector organ [14, 15].

We don't have the time and the tools to further investigate. However, our data, supported by similar observations by French colleagues and British Rhinological Society, leads to the following consideration: anosmic/hyposmic subjects,

\*Address correspondence to this author at the Giuseppe Chiarella, Unit of Audiology, Department of Experimental and Clinical Medicine, Magna Graecia University, Campus S. Venuta, 88100, Catanzaro, Italy; E-mail: [chiarella@unicz.it](mailto:chiarella@unicz.it)

#All Authors contributed equally to the work.

usually presenting without obstructive nasal conditions, should be regarded as potential COVID-19 cases. Therefore, we should avoid nasal treatments (*i.e.* nasal washing, spray, invasive maneuvers, *etc.*) that amplify the virus dissemination. Viral shedding from nasal secretions, sneezing, coughing, and sputum can be continuous up to six weeks, which builds concerns that asymptomatic individuals could also transmit the infection to others [16]. All healthcare personnel, especially practitioners in Otolaryngology, Audiology, and Phoniatrics, are hence the most exposed to infection risk, in addition to Wuhan's documented risks for ENT and Ophthalmologists.

### CONSENT FOR PUBLICATION

Not applicable.

### FUNDING

None.

### CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

### ACKNOWLEDGEMENTS

We want to thank the following for their precious contribution:

Giandomenico Maggiore, Otolaryngology, Head and Neck Surgery, A.O.U. "Careggi", Florence, Italy

Gianluca Leopardi, Otolaryngology Unit, S. Giuseppe Hospital, Empoli, Firenze, Italy

Teodoro Aragona, Otolaryngology Unit, Ospedali Riuniti, Ancona, Italy

Mariarosa Caruso, USC Nefrologia, ASST Papa Giovanni XXIII, Bergamo, Italy

Mario Ciniglio Appiani, Otolaryngology Unit, Santo Stefano Hospital, Prato, Italy

Andrea Pennacchi, Otolaryngology Unit, Engles Profili Hospital, Fabriano, Ancona, Italy

### REFERENCES

[1] Commission WMHCMH Report of clustering pneumonia of unknown etiology in Wuhan City <http://wjwwuhangovcn/front/web/showDetail/20191231089892019>.

[2] Zhu N, Zhang D, Wang W, *et al.* China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; 382(8): 727-33. <http://dx.doi.org/10.1056/NEJMoa2001017> PMID: 31978945

[3] WHO. WHO Novel coronavirus China <http://www.hoint/csr/don/12-january-2020-novel-coronavirus-china/en/2020>.

[4] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol* 2019; 17(3): 181-92. <http://dx.doi.org/10.1038/s41579-018-0118-9> PMID: 30531947

[5] Alexandra C. Walls Y-JP, M. Alexandra Tortorici, Abigail Wall, Andrew T. McGuire, David Velesler. Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. *bioRxiv* 2020.

[6] Wrapp D, Wang N, Corbett KS, *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020; 367(6483): 1260-3. <http://dx.doi.org/10.1126/science.abb2507> PMID: 32075877

[7] Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* 2020; 5(4): 562-9. <http://dx.doi.org/10.1038/s41564-020-0688-y> PMID: 32094589

[8] Li W, Moore MJ, Vasilieva N, *et al.* Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003; 426(6965): 450-4. <http://dx.doi.org/10.1038/nature02145> PMID: 14647384

[9] Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395(10223): 497-506. [http://dx.doi.org/10.1016/S0140-6736\(20\)30183-5](http://dx.doi.org/10.1016/S0140-6736(20)30183-5) PMID: 31986264

[10] Wu JT, Leung K, Bushman M, *et al.* Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. *Nat Med* 2020.

[11] Gentile I, Abenavoli L. COVID-19: Perspectives on the Potential Novel Global Threat. *Rev Recent Clin Trials* 2020; 15(2): 84-6. <http://dx.doi.org/10.2174/1574887115999200228100745> PMID: 32116200

[12] Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. *Front Cell Neurosci* 2018; 12: 386. <http://dx.doi.org/10.3389/fncel.2018.00386> PMID: 30416428

[13] Swanson PA II, McGavern DB. Portals of viral entry into the central nervous system. *The Blood-Brain Barrier in Health and Disease*. Boca Raton, FL: CRC Press 2015; pp. 23-47. <http://dx.doi.org/10.1201/b19299-3>

[14] Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. *ACS Chem Neurosci* 2020; 11(7): 995-8. <http://dx.doi.org/10.1021/acscchemneuro.0c00122> PMID: 32167747

[15] Durrant DM, Ghosh S, Klein RS. The olfactory Bulb: An immunosensory effector organ during neurotropic viral infections. *ACS Chem Neurosci* 2016; 207(4): 464-469.

[16] Ramadan N, Shaib H. Middle east respiratory syndrome coronavirus (MERS-CoV): A review. *Germs*. 2019 Mar 1; 9(1): 35-42. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. *Front Cell Neurosci* 2018; 12: 386.